Literature DB >> 7785638

High-dose localized radiation therapy for treatment of hepatic malignant tumors: CT findings and their relation to radiation hepatitis.

S A Yamasaki1, C S Marn, I R Francis, J M Robertson, T S Lawrence.   

Abstract

OBJECTIVE: High-dose radiation therapy of the liver performed using overlapping portals defined by a three-dimensional treatment-planning system (conformal radiation therapy) is a new method of treating hepatic tumors. This study was performed to delineate the differences in the CT appearances of the liver after therapy compared with other methods of radiotherapy and to correlate imaging findings to clinical findings of radiation hepatitis.
MATERIALS AND METHODS: Contrast-enhanced CT scans were obtained at 8- to 12-week intervals on 31 consecutive patients with primary or metastatic hepatic malignant tumors. All had undergone high-dose conformal radiation therapy and injection of fluorodeoxyuridine into the hepatic artery as part of the treatment for unresectable hepatic neoplasms. Tumor size, location, presence of changes within the target volume after therapy, presence of atrophy of the treated segments or hypertrophy of the untreated segments, ascites, and any changes in adjacent organs seen on serial CT scans obtained before and after treatment were recorded. Clinical records were reviewed for evidence of radiation hepatitis (nonmalignant ascites evident on physical examination and a twofold elevation of alkaline phosphatase in the anicteric patient).
RESULTS: In 23 (74%) of the 31 patients, follow-up CT studies after treatment showed a low-attenuation area adjacent to the hepatic tumor in the target volume. In two patients with fatty infiltration of the liver, CT showed relative increased density in the treatment portal. A sharp, straight interface was rarely seen at the treatment margin. Maximal effect was seen 2-3 months after completion of therapy and persisted for up to 3 months. Atrophy in the treated segment or lobe was seen in four patients, hypertrophy of the untreated liver was seen in four patients, and both effects were seen in seven patients. Extrahepatic effects included segmental right renal atrophy in three patients and duodenal wall thickening in two patients. Only two patients (6%) in this series had clinical evidence of radiation hepatitis.
CONCLUSION: High-dose localized radiotherapy of the liver results in reversible hypodense regions in the liver parenchyma within the target volume that do not have a sharp interface delineating the radiation portal. This appearance should not be confused with tumor progression or irreversible liver injury. The changes evident on CT scans after therapy are not predictive of radiation hepatitis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7785638     DOI: 10.2214/ajr.165.1.7785638

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  15 in total

Review 1.  Hepatic radiation toxicity: avoidance and amelioration.

Authors:  Chandan Guha; Brian D Kavanagh
Journal:  Semin Radiat Oncol       Date:  2011-10       Impact factor: 5.934

Review 2.  Radiation-associated liver injury.

Authors:  Charlie C Pan; Brian D Kavanagh; Laura A Dawson; X Allen Li; Shiva K Das; Moyed Miften; Randall K Ten Haken
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

3.  Monitoring of liver metastases after stereotactic radiotherapy using low-MI contrast-enhanced ultrasound--initial results.

Authors:  M Krix; C Plathow; M Essig; K Herfarth; J Debus; H-U Kauczor; S Delorme
Journal:  Eur Radiol       Date:  2005-02-24       Impact factor: 5.315

4.  A nonhuman primate model of human radiation-induced venocclusive liver disease and hepatocyte injury.

Authors:  Govardhana Rao Yannam; Bing Han; Kentaro Setoyama; Toshiyuki Yamamoto; Ryotaro Ito; Jenna M Brooks; Jorge Guzman-Lepe; Csaba Galambos; Jason V Fong; Melvin Deutsch; Mubina A Quader; Kosho Yamanouchi; Rafi Kabarriti; Keyur Mehta; Alejandro Soto-Gutierrez; Jayanta Roy-Chowdhury; Joseph Locker; Michio Abe; Charles A Enke; Janina Baranowska-Kortylewicz; Timothy D Solberg; Chandan Guha; Ira J Fox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-12-05       Impact factor: 7.038

5.  FDG-Avid Focal Liver Reaction From Proton Therapy in a Patient With Primary Esophageal Adenocarcinoma.

Authors:  Hena S Ahmed; Austin R Pantel; James M Metz; John P Plastaras; Michael D Farwell
Journal:  Clin Nucl Med       Date:  2018-05       Impact factor: 7.794

6.  CT evaluations of focal liver reactions following stereotactic body radiotherapy for small hepatocellular carcinoma with cirrhosis: relationship between imaging appearance and baseline liver function.

Authors:  N Sanuki-Fujimoto; A Takeda; T Ohashi; E Kunieda; S Iwabuchi; K Takatsuka; N Koike; N Shigematsu
Journal:  Br J Radiol       Date:  2010-12       Impact factor: 3.039

Review 7.  Gastrointestinal radiation injury: symptoms, risk factors and mechanisms.

Authors:  Abobakr K Shadad; Frank J Sullivan; Joseph D Martin; Laurence J Egan
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

8.  An isolate alpha-fetoprotein producing gastric cancer liver metastasis emerged in a patient previously affected by radiation induced liver disease.

Authors:  Vincenzo Cardinale; Gianmaria De Filippis; Alessandro Corsi; Augusto La Penna; Michele Rossi; Carlo Catalano; Paolo Bianco; Adriano De Santis; Domenico Alvaro
Journal:  World J Hepatol       Date:  2013-07-27

9.  Radiation-induced liver injury mimicking liver metastases on FDG-PET-CT after chemoradiotherapy for esophageal cancer : A retrospective study and literature review.

Authors:  Francine E M Voncken; Berthe M P Aleman; Jolanda M van Dieren; Cecile Grootscholten; Ferry Lalezari; Johanna W van Sandick; Jeffrey D Steinberg; Erik Vegt
Journal:  Strahlenther Onkol       Date:  2017-10-19       Impact factor: 3.621

10.  Image-based response assessment of liver metastases following stereotactic body radiotherapy with respiratory tracking.

Authors:  Hajer Jarraya; Xavier Mirabel; Sophie Taieb; Sylvain Dewas; Emmanuelle Tresch; Francois Bonodeau; Antoine Adenis; Andrew Kramar; Eric Lartigau; Luc Ceugnart
Journal:  Radiat Oncol       Date:  2013-01-30       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.